Company
Lilly
Official Name: Eli Lilly and Company
Headquarters: Indianapolis, IN, United States
Founded: 1876
Employees: 35,000
CEO: Mr. David A. Ricks
Market Cap
$586.39 Billion
USD as of Jan. 1, 2024
Company Description
Eli Lilly and Company, more simply known as Eli Lilly or just Lilly, is a pharmaceutical company. Founded in 1876, Eli Lilly is engaged in the research, development, manufacturing, and marketing of insulin and endocrinology products for diabetes, psychiatric medication including Prozac, as well as treatments for osteoporosis, human growth hormone deficiency, pediatric growth conditions, autoimmune diseases, and diverse types of cancers.
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—General
| Company | Market Cap (USD) |
|---|---|
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
| AbbVie | $285.06 B |
| Roche | $240.44 B |
| Novartis | $220.27 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
| AbbVie | $285.06 B |
Detailed Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Stocks & Indices
Eli Lilly and Company has the following listings and related stock indices.
Stock: NYSE: LLY wb_incandescent
Stock: FSX: LLY wb_incandescent
Stock: XETR: LLY wb_incandescent
Product & Services
Pharmaceutical drugs
Key People
Founder(s): Eli Lilly
David A. Ricks (Chairperson, President, & CEO) Anat Ashkenazi (Vice president & CFO)
Financials
Revenue: US$22.319 billion (2019)
Operating income: US$5.595 billion (2019)
Net income: US$8.318 billion (2019)
Total assets: US$39.286 billion (2019)
Total equity: US$2.699 billion (2019)